Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Brain vulnerability and viability after ischaemia

NATURE REVIEWS | Neuroscience, 21.07.2021

Stefano G. Daniele1,2,3, Georg Trummer4, Konstantin A. Hossmann5, Zvonimir Vrselja1,2, Christoph Benk4, Kevin T. Gobeske6, Domagoj Damjanovic4, David Andrijevic 1,2, Jan- Steffen Pooth 4, David Dellal7, Friedhelm Beyersdorf 4 ✉ and Nenad Sestan1,2,8,9,10,11,12


The susceptibility of the brain to ischaemic injury dramatically limits its viability following interruptions in blood flow. However, data from studies of dissociated cells, tissue specimens, isolated organs and whole bodies have brought into question the temporal limits within which the brain is capable of tolerating prolonged circulatory arrest. This Review assesses cell type- specific mechanisms of global cerebral ischaemia, and examines the circumstances in which the brain exhibits heightened resilience to injury. We suggest strategies for expanding such discoveries to fuel translational research into novel cytoprotective therapies, and describe emerging technologies and experimental concepts. By doing so, we propose a new multimodal framework to investigate brain resuscitation following extended periods of circulatory arrest.

Owing to its high metabolic demand and limited energy reserves1, the brain is highly susceptible to ischaemic  injury. The most common clinical manifestation of cerebral ischaemia is stroke, which results from interruptions in focal blood flow, and affects approximately 800,000 people per year in the United States 2. A more extreme insult known as global cerebral ischaemia occurs when blood flow to the brain stops entirely, such as in the case of cardiac arrest (CA), affecting nearly 350,000 people per year in the United States2. The potential for positive outcomes with stroke treatments has steadily increased over the past decades, but brain resuscitation after CA remains a largely unsolved clinical problem.

To guide treatment options for global ischemia during CA, a three- phase, time- sensitive model was proposed in the early 2000s3. This model consists of electrical (0–4 min after CA), circulatory (4–10 min) and metabolic (more than 10 min) phases, which reflect the temporal progression of ischemic injury and resuscitation physiology. Most cases of out- of- hospital CA (OHCA) present in the metabolic phase, for which current treatment options are limited. Indeed, OHCA outcomes remain disappointingly poor, with  pproximately 10% of patients surviving to hospital discharge2. Furthermore, even if cardiac function is restored, more than half of surviving patients display persistent brain damage and reduced quality of life2,4. Therefore, the vulnerability of the brain to ischaemia is a major limiting factor for successful resuscitation with positive neurological outcomes. Much of our current understanding of cerebral ischaemic injury comes from the use of experimental…

Fortsetzung: https://resuscitec.de/wp-content/uploads/2021/03/Nature-2021.pdf


Resuscitec GmbH
Engesserstraße 4
D-79108 Freiburg


Sie erhalten das Presseclipping der Resuscitec GmbH aufgrund Ihrer Beziehung zu unserem Unternehmen. Wir verarbeiten Ihre Daten auf Grundlage unseres berechtigten Interesses zum Zweck der persönlichen Ansprache und zum Versand unseres Presseclippings. Verantwortlich für die Datenverarbeitung ist die Resuscitec GmbH. Weitere Informationen zum Datenschutz finden Sie in unseren Datenschutzhinweisen. Sie können der Verarbeitung Ihrer personenbezogenen Daten für den Versand des Presseclippings jederzeit formlos widersprechen.


Aus urheberrechtlichen Gründen dürfen die Artikel weder in digitaler noch ausgedruckter Form an Dritte weitergegeben werden. Sie sind nur zum persönlichen Gebrauch bestimmt, der Aufbau einer Datenbank mit digitalisierten Artikeln ist nicht erlaubt.